Search Result

Results for "

platelet P2Y12 receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (1) Calcium Channel (1) Drug Derivative (1) Drug Metabolite (5) ERK (1) Estrogen Receptor/ERR (1) Ferroptosis (1) FXR (1) G protein-coupled Bile Acid Receptor 1 (1) Glutathione Reductase (GR) (1) Isotope-Labeled Compounds (7) mTOR (1) P2Y Receptor (36) p38 MAPK (1) PI3K (1) Reference Standards (5) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (35) Inflammation/Immunology (5) Metabolic Disease (1) Neurological Disease (3)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Platelet-activating Factor Receptor (PAFR) PDGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10064

Ticagrelor 10+ Cited Publications AZD6140; AR-C 126532XX	P2Y Receptor	Cardiovascular Disease Cancer
Ticagrelor (AZD6140) is a reversible oral *P2Y12* receptor antagonist for the treatment of platelet aggregation.

HY-15283

Clopidogrel Maximum Cited Publications 30 Publications Verification Clopidogrelum	P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel is an orally active platelet inhibitor that targets *P2Y12* receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

HY-108660

PSB-0739 1 Publications Verification	P2Y Receptor	Cardiovascular Disease
PSB-0739 is a high-affinity potent, competitive, nonselective platelet **P2Y₁₂ receptor** antagonist with a K_i values of 24.9 nM. The P2Y₁₂ receptor plays a crucial role in platelet aggregation. Antithrombotic effect .

HY-15284

Prasugrel 1 Publications Verification PCR 4099	P2Y Receptor	Cardiovascular Disease
Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent *P2Y12* receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284A

Prasugrel hydrochloride 1 Publications Verification PCR 4099 hydrochloride	P2Y Receptor	Cardiovascular Disease
Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent *P2Y12* receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-108648

2-MeS-ADP trisodium 2-Methylthioadenosine diphosphate trisodium; 2-Methylthio-ADP trisodium	P2Y Receptor	Neurological Disease
2-Methylthioadenosine diphosphate trisodium is a potent purinergic P2Y receptors agonist, with EC₅₀s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-Methylthioadenosine diphosphate trisodium has pEC₅₀s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-Methylthioadenosine diphosphate trisodium induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1 .

HY-109122

Selatogrel ACT-246475	P2Y Receptor	Cardiovascular Disease
Selatogrel (ACT-246475) is a reversible and selective *P2Y₁₂* receptor antagonist which inhibits platelet aggregation with an IC₅₀ of 8 nM. Selatogrel exhibits antithrombotic efficacy .

HY-107867

(±)-Clopidogrel bisulfate	P2Y Receptor	Cardiovascular Disease Inflammation/Immunology
(±)-Clopidogrel bisulfate is a platelet **P2Y12 receptor** inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

HY-N0910

Notoginsenoside Ft1 1 Publications Verification	PI3K mTOR Akt Apoptosis p38 MAPK ERK Transmembrane Glycoprotein Glutathione Reductase (GR) Estrogen Receptor/ERR Calcium Channel Ferroptosis G protein-coupled Bile Acid Receptor 1 FXR	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 ⁺ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca ²⁺ accumulation, reduces cAMP levels by activating a signaling network mediated through *P2Y₁₂* receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance .

HY-123669A

trans-R-138727	P2Y Receptor	Cardiovascular Disease
Trans-R-138727 is the trans isomer of R-138727 (HY-123669). R-138727 is the active metabolite of the antiplatelet agent Prasugrel (HY-15284). R-138727 is an irreversible inhibitor for the platelet receptor P2Y12, and inhibits ADP-induced platelet activation and aggregation .

HY-108648A

2-MeSADP 2-Methylthioadenosine diphosphate; 2-Methylthio-ADP	P2Y Receptor	Neurological Disease
2-MeSADP is a P2Y receptor agonist, with an EC₅₀ of 5 nM for human P2Y12, EC₅₀ values of 19 nM and 13 nM for human P2Y13, and an EC₅₀ of 6.2 nM for mouse P2Y13. It shows slightly higher selectivity for P2Y12 over human P2Y13. 2-MeSADP triggers increases in intracellular calcium levels, Gi-mediated cAMP inhibition, adenylate cyclase inhibition and downstream signal transduction. 2-MeSADP can be used in research related to glaucoma .

HY-123669

R-138727	P2Y Receptor Drug Metabolite	Cardiovascular Disease
R-138727, the major active metabolite of Prasugrel (HY-15284), is a highly potent and selective irreversible antagonist of the P2Y12 receptor, with an IC₅₀ of 2.5 μM. R-138727 covalently binds to the P2Y12 receptor on the platelet surface, blocking adenosine diphosphate-mediated platelet activation and aggregation. R-138727 can be used to study stroke, cerebral infarction and neurological deficits.

HY-10064S

Ticagrelor-d7 1 Publications Verification	Isotope-Labeled Compounds P2Y Receptor	Cardiovascular Disease Cancer
Ticagrelor-d₇ is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation .

HY-77734

AR-C133913XX	Drug Metabolite	Cardiovascular Disease
AR-C124910XX is a metabolite of Ticagrelor (HY-10064 ). Ticagrelor is a reversible oral *P2Y12* receptor antagonist, and can be used for study of platelet aggregation .

HY-133781

cis-Clopidogrel-MP derivative Clopidogrel-MP-AM	Drug Metabolite	Others
cis-Clopidogrel-MP derivative (Clopidogrel-MP-AM) is a 3’-methoxyacetophenone derivative of Clopidogrel active metabolite . Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor .

HY-15284S2

Prasugrel-d4 PCR 4099-d₄	P2Y Receptor	Cardiovascular Disease
Prasugrel-d₄ is the deuterium labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-123490

Regrelor disodium INS50589	P2Y Receptor	Inflammation/Immunology
Regrelor disodium (INS 50589) is a platelet *P2Y12* receptor antagonist. Regrelor disodium is a well-tolerated, reversible ADP competitive antagonist. Regrelor disodium inhibits cell proliferation. Regrelor disodium can be used in inflammation-related research .

HY-136501

MRS2395	P2Y Receptor	Cardiovascular Disease
MRS2395, an dipivaloyl derivative, is a potent *P2Y12* receptor antagonist. MRS2395 inhibits ADP-induced platelet activation with a K_i of 3.6 μM. MRS2395 inhibits cAMP induced by ADP in rat platelets in the presence of PGE1 with an IC₅₀ of 7 µM. MRS2395 enhances platelet dense granule release in response to TRAP-6 .

HY-148300

AR-C66096	P2Y Receptor	Cardiovascular Disease
AR-C66096 is a potent and selective antagonist of the Gi-coupled **P2Y12 receptor*. AR-C66096 suppresses platelet* thrombus stability under physiological flow conditions. AR-C66096 inhibits ADP-induced aggregation in whole blood aggregometry. AR-C66096 can be used for antithrombotic research .

HY-163645

P2Y12 antagonist 1	P2Y Receptor	Cardiovascular Disease
P2Y12 antagonist 1 (compound 26) is a P2Y12 receptor antagonist with a Ki of 3.13 μM. P2Y12 antagonist 1 can be used to inhibit platelet aggregation and is a potential antithrombotic agent .

HY-15284B

Prasugrel (Maleic acid) PCR 4099 (Maleic acid)	P2Y Receptor	Cardiovascular Disease
Prasugrel (PCR 4099) Maleic acid is a thienopyridine and proagent, inhibits platelet function. Prasugrel Maleic acid is an orally active and potent *P2Y12* receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-172417

Becondogrel 2-Oxoclopidogrel	P2Y Receptor	Cardiovascular Disease
Becondogrel (2-Oxoclopidogrel) is the metabolite of Clopidogrel (HY-15283). Becondogrel irreversibly inhibits **P2Y12 receptor*, thereby inhibiting platelet* aggregation and thrombosis .

HY-10064R

Ticagrelor (Standard) AZD6140 (Standard); AR-C 126532XX (Standard)	Reference Standards P2Y Receptor	Cardiovascular Disease Cancer
Ticagrelor (Standard) is the analytical standard of Ticagrelor. This product is intended for research and analytical applications. Ticagrelor (AZD6140) is a reversible oral *P2Y12* receptor antagonist for the treatment of platelet aggregation.

HY-15284S1

Prasugrel-d3 PCR 4099-d₃	P2Y Receptor	Cardiovascular Disease
Prasugrel-d₃ is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S

Prasugrel-d5 PCR 4099-d₅	Isotope-Labeled Compounds P2Y Receptor	Cardiovascular Disease
Prasugrel-d₅ is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-10064S1

Ticagrelor-d4 AZD6140-d₄; AR-C 126532XX-d₄	Isotope-Labeled Compounds P2Y Receptor	Cardiovascular Disease Cancer
Ticagrelor-d₄ (AZD6140-d₄) is deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral *P2Y12* receptor antagonist for the treatment of platelet aggregation.

HY-119085

ACT-281959	P2Y Receptor	Cardiovascular Disease
ACT-281959 is an orally active prodrug of Selatogrel (HY-109122), a *P2Y12* receptor antagonist. ACT-281959 can inhibit platelet aggregation and can be used for the research of cardiovascular disease .

HY-15284R

Prasugrel (Standard) PCR 4099 (Standard)	Reference Standards P2Y Receptor	Cardiovascular Disease
Prasugrel (Standard) is the analytical standard of Prasugrel. This product is intended for research and analytical applications. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent *P2Y12* receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284AR

Prasugrel hydrochloride (Standard) PCR 4099 hydrochloride (Standard)	Reference Standards P2Y Receptor	Cardiovascular Disease
Prasugrel (hydrochloride) (Standard) is the analytical standard of Prasugrel (hydrochloride). This product is intended for research and analytical applications. Prasugrel hydrochloride (PCR 4099 hydrochloride), a thienopyridine and proagent, inhibits platelet function. Prasugrel hydrochloride is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-136142

Prasugrel chloride impurity	Drug Metabolite	Others
Prasugrel chloride impurity is a catp impurity of Prasugrel, exacted from patent US20130345428A1, line 0053. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S3

Prasugrel-13C6 PCR 4099-¹³C₆	Isotope-Labeled Compounds P2Y Receptor	Cardiovascular Disease
Prasugrel-13C6 is a deuterated labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent *P2Y12* receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15283R

Clopidogrel (Standard) Clopidogrelum (Standard)	Reference Standards P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel (Standard) is the analytical standard of Clopidogrel. This product is intended for research and analytical applications. Clopidogrel is an orally active platelet inhibitor that targets *P2Y12* receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

HY-W419570

(Rac)-BX 048	P2Y Receptor	Cardiovascular Disease
(Rac)-BX 048 is a BX 048 racemate. BX 048 is a *P2Y12* receptor antagonist. BX 048 inhibits ADP-induced platelet aggregation in human, dog and rat whole blood. BX 048 also inhibits Arachidonic acid (HY-109590) induced platelet aggregation (IC₅₀ of 15 μM) .

HY-W686186

Prasugrel hydroxy thiolactone	Drug Metabolite P2Y Receptor	Cardiovascular Disease
Prasugrel hydroxy thiolactone (compound M18) is a metabolite of Prasugrel (HY-15284). Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits Adenosine 5'-diphosphate (ADP, HY-W010918)-induced platelet aggregation .

HY-107867S1

(Rac)-Clopidogrel hydrogen-d9 sulfate	Isotope-Labeled Compounds P2Y Receptor	Inflammation/Immunology
(Rac)-Clopidogrel hydrogen-d₉ sulfate is the deuterium labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

HY-107867S2

Clopidogrel-13C,d3 sulfate	Isotope-Labeled Compounds P2Y Receptor	Cardiovascular Disease
Clopidogrel- ¹³C,d₃ sulfate is the deuterium and ¹³C-labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

HY-108660R

PSB-0739 (Standard)	Reference Standards P2Y Receptor	Cardiovascular Disease
PSB-0739 (Standard) is the analytical standard of PSB-0739 (HY-108660). This product is intended for research and analytical applications. PSB-0739 is a high-affinity potent, competitive, nonselective platelet P2Y12 receptor antagonist with a K_i values of 24.9 nM. The P2Y12 receptor plays a crucial role in platelet aggregation. Antithrombotic effect .

HY-12435

SAR216471	P2Y Receptor	Cardiovascular Disease
SAR216471 is a *P2Y12* receptor antagonist. SAR216471 reversibly blocks the binding of 2MeSADP to P2Y12 receptors in vitro with an IC₅₀ of 17 nM. SAR216471 can result in the inhibition of platelet aggregation. SAR216471 exhibits anti-thrombotic activity in rat model. SAR216471 can be studied in research on thrombosis .

HY-109122A

Selatogrel hydrochloride ACT-246475 hydrochloride	P2Y Receptor	Cardiovascular Disease
Selatogrel (ACT-246475) is a reversible and selective *P2Y₁₂* receptor antagonist which inhibits platelet aggregation with an IC₅₀ of 8 nM. Selatogrel exhibits antithrombotic efficacy .

HY-15283AS1

(±)-Clopidogrel-d4 (±)-Clopidogrelum-d⁴	Isotope-Labeled Compounds P2Y Receptor	Cardiovascular Disease Inflammation/Immunology
(±)-Clopidogrel-d₄ ((±)-Clopidogrelum-d₄) is the deuterium labeled (±)-Clopidogrel (HY-107867). (±)-Clopidogrel is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel has anti-inflammatory effects .

HY-182012

DT-678	Drug Derivative	Cardiovascular Disease
DT-678 is an orally active antiplatelet and antithrombotic inhibitor. DT-678 is a conjugate formed by linking the active metabolite of Clopidogrel (HY-15283) with 3-nitropyridine-2-thiol via a mixed disulfide bond. DT-678 does not rely on CYP2C19 for activation, and directly releases active substances via thiol exchange reactions in vivo, exhibiting superior efficacy over Clopidogrel. DT-678 can be used in research related to acute coronary syndrome and thrombosis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0910

Notoginsenoside Ft1 1 Publications Verification	Triterpenes Structural Classification Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow Classification of Application Fields Terpenoids Other Diseases Plants Disease Research Fields Araliaceae Source Classification	PI3K mTOR Akt Apoptosis p38 MAPK ERK Transmembrane Glycoprotein Glutathione Reductase (GR) Estrogen Receptor/ERR Calcium Channel Ferroptosis G protein-coupled Bile Acid Receptor 1 FXR
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 ⁺ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca ²⁺ accumulation, reduces cAMP levels by activating a signaling network mediated through *P2Y₁₂* receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance .

Cat. No.	Product Name	Chemical Structure

HY-10064S

Ticagrelor-d7 1 Publications Verification
Ticagrelor-d₇ is the deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral P2Y12 receptor antagonist for the treatment of platelet aggregation .

HY-15284S2

Prasugrel-d4
Prasugrel-d₄ is the deuterium labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S1

Prasugrel-d3
Prasugrel-d₃ is the deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-15284S

Prasugrel-d5
Prasugrel-d₅ is deuterium labeled Prasugrel. Prasugrel (PCR 4099), a thienopyridine and prodrug, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-10064S1

Ticagrelor-d4
Ticagrelor-d₄ (AZD6140-d₄) is deuterium labeled Ticagrelor. Ticagrelor (AZD6140) is a reversible oral *P2Y12* receptor antagonist for the treatment of platelet aggregation.

HY-15284S3

Prasugrel-13C6
Prasugrel-13C6 is a deuterated labeled Prasugrel . Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent *P2Y12* receptor antagonist, and inhibits ADP-induced platelet aggregation .

HY-107867S1

(Rac)-Clopidogrel hydrogen-d9 sulfate

(Rac)-Clopidogrel hydrogen-d₉ sulfate is the deuterium labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

HY-107867S2

Clopidogrel-13C,d3 sulfate

Clopidogrel- ¹³C,d₃ sulfate is the deuterium and ¹³C-labeled (±)-Clopidogrel (bisulfate) (HY-107867). (±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .

HY-15283AS1

(±)-Clopidogrel-d4

(±)-Clopidogrel-d₄ ((±)-Clopidogrelum-d₄) is the deuterium labeled (±)-Clopidogrel (HY-107867). (±)-Clopidogrel is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel has anti-inflammatory effects .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P87002

	P2Y12 Antibody (YA6695) 1 Publications Verification ADP glucose receptor antibody; ADP-glucose receptor antibody; ADPG R antibody; ADPG-R antibody; ADPGR antibody; BDPLT8 antibody; G protein coupled receptor SP1999 antibody; Gi coupled ADP receptor HORK 3 antibody; Gi coupled ADP receptor HORK3 antibody; HORK 3 antibody; ADP glucose receptor antibody; ADP-glucose receptor antibody; ADPG R antibody; ADPG-R antibody; ADPGR antibody; BDPLT8 antibody; G protein coupled receptor SP1999 antibody; Gi coupled ADP receptor HORK 3 antibody; Gi coupled ADP receptor HORK3 antibody; HORK 3 antibody; HORK3 antibody; P2RY 12 antibody; P2RY12 antibody; P2T(AC) antibody; P2Y 12 antibody; P2Y purinoceptor 12 antibody; P2Y(12)R antibody; P2Y(AC) antibody; P2Y(ADP) antibody; P2Y(cyc) antibody; P2Y12 antibody; P2Y12 platelet ADP receptor antibody; P2Y12_HUMAN antibody; platelet ADP receptor antibody; Purinergic receptor P2RY12 antibody; Purinergic receptor P2Y G protein coupled 12 antibody; Purinergic receptor P2Y12 antibody; Putative G protein coupled receptor antibody; SP 1999 antibody; SP1999 antibody;	IHC-F, IHC-P	Mouse, Rat
	P2Y12 Antibody (YA6695) is a Rat -derived and non-conjugated IgG1 monoclonal antibody, targeting to P2Y12.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks